Skip to main
SYK

Stryker (SYK) Stock Forecast & Price Target

Stryker (SYK) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 42%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Stryker demonstrated significant financial growth across several key segments, with knee procedures recording a notable increase of 7.6% in the U.S. and 8.8% internationally, alongside strong performance in robotic-assisted technologies. The company achieved an impressive operating margin of 30.2%, reflecting a year-over-year improvement driven by robust sales activity, particularly in new Mako installations, and organic sales growth reaching 11.0% in the most recent quarter. Additionally, Stryker's peripheral vascular and neurotechnology divisions experienced substantial growth, contributing to total sales of $4.562 billion, which surpassed consensus expectations and underscored the company's broad-based strength across its diverse product offerings.

Bears say

Stryker faces several challenges that contribute to a negative outlook, including potential disruptions from recent acquisitions and a deceleration in Mako system utilization amid increased competition. Organic revenue growth is projected to slow to 8% or less due to unsuccessful new product launches and revenue dis-synergies, which may lead to below-consensus earnings performance. Additionally, Stryker's gross margin declined to 65.2%, falling short of consensus expectations, while ongoing risks such as slower orthopedic market growth and a decline in hospital capital spending could further impact the company's financial standing.

Stryker (SYK) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 42% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stryker and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stryker (SYK) Forecast

Analysts have given Stryker (SYK) a Buy based on their latest research and market trends.

According to 12 analysts, Stryker (SYK) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $429.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $429.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stryker (SYK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.